Literature DB >> 22216857

Hepatocellular carcinoma.

Emmanuel A Tsochatzis, Tim Meyer, Andrew K Burroughs.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22216857     DOI： 10.1056/NEJMc1112501

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  24 in total

1.  ART and science in using transarterial chemoembolization for retreating patients with hepatocellular carcinoma.

Authors:  Evangelia M Fatourou; Emmanuel A Tsochatzis
Journal:  Hepatobiliary Surg Nutr       Date:  2014-12       Impact factor: 7.293

Review 2.  Transarterial chemoembolization and bland embolization for hepatocellular carcinoma.

Authors:  Emmanuel A Tsochatzis; Evangelia Fatourou; James O'Beirne; Tim Meyer; Andrew K Burroughs
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

3.  Upregulated expression of polycomb protein Ring1 contributes to poor prognosis and accelerated proliferation in human hepatocellular carcinoma.

Authors:  Yicheng Xiong; Baoying Hu; Lixian Wei; Dawei Jiang; Mingyan Zhu
Journal:  Tumour Biol       Date:  2015-07-04

4.  Epigallocatechin Gallate Induces Hepatic Stellate Cell Senescence and Attenuates Development of Hepatocellular Carcinoma.

Authors:  Mozhdeh Sojoodi; Lan Wei; Derek J Erstad; Suguru Yamada; Tsutomu Fujii; Hadassa Hirschfield; Rosa S Kim; Gregory Y Lauwers; Michael Lanuti; Yujin Hoshida; Kenneth K Tanabe; Bryan C Fuchs
Journal:  Cancer Prev Res (Phila)       Date:  2020-04-06

Review 5.  Downstaging for hepatocellular cancer: harm or benefit?

Authors:  Kathleen Bryce; Emmanuel A Tsochatzis
Journal:  Transl Gastroenterol Hepatol       Date:  2017-12-12

6.  Suppression of the nuclear transporter-KPNβ1 expression inhibits tumor proliferation in hepatocellular carcinoma.

Authors:  Linlin Yang; Baoying Hu; Yixin Zhang; Songlin Qiang; Jin Cai; Wei Huang; Chen Gong; Tingting Zhang; ShuSen Zhang; Pan Xu; Xuming Wu; Jibin Liu
Journal:  Med Oncol       Date:  2015-03-21       Impact factor: 3.064

7.  MiR-491 attenuates cancer stem cells-like properties of hepatocellular carcinoma by inhibition of GIT-1/NF-κB-mediated EMT.

Authors:  Xiaojun Yang; Jing Ye; Han Yan; Zhaoyang Tang; Jian Shen; Jianping Zhang; Lihua Yang
Journal:  Tumour Biol       Date:  2015-07-19

8.  The downregulation of ErbB3 binding protein 1 (EBP1) is associated with poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.

Authors:  Baoying Hu; Yicheng Xiong; Runzhou Ni; Lixian Wei; Dawei Jiang; Gang Wang; Di Wu; Tianxin Xu; Fengbo Zhao; Mingyan Zhu; Chunhua Wan
Journal:  Mol Cell Biochem       Date:  2014-08-01       Impact factor: 3.396

9.  Overexpression of SYF2 correlates with enhanced cell growth and poor prognosis in human hepatocellular carcinoma.

Authors:  Shusen Zhang; Weidong Shi; Yuyan Chen; Zhiwei Xu; Jia Zhu; Tingting Zhang; Wei Huang; Runzhou Ni; Cuihua Lu; Xiubing Zhang
Journal:  Mol Cell Biochem       Date:  2015-08-11       Impact factor: 3.396

10.  Decreased expression levels of ELOVL6 indicate poor prognosis in hepatocellular carcinoma.

Authors:  Hui Li; Xianling Wang; Jun Tang; Haibo Zhao; Min Duan
Journal:  Oncol Lett       Date:  2019-10-09       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.